1920s drug shifts into today’s alcohol addiction arena

EH Paris correspondent Annick Chapoy, reports on a French study that confirms the relevance of a drug with a long history in the management of other diseases

According to a preliminary study led by a team of French doctors, high-dose baclofen can be efficient against addiction to alcohol, opening the way for clinical tests to precisely assess the use of that muscle-relaxant drug to treat the illness. Bacoflen is not new. Formulated in the 1920s, the medicine is primarily used in neurology, spasticity and multiple sclerosis, but is increasingly prescribed for alcohol dependency. In 2008, its popularity was boosted by the publication of ‘The end of my addiction’, a book written by cardiologist Olivier Ameisen, an alcoholic, to describe how he experimented with the drug on himself. Used at high-dose levels, baclofen totally suppressed his craving for alcohol – indeed he reports that he became effortlessly ‘indifferent’ to it.

‘We estimate that between 20-30,000 people use baclofen today in France for alcohol problems; that’s a lot,’ says Dr Philippe Jaury, of the University of Paris-Descartes, who is the main author of the retrospective ‘open’ study published in Alcohol and Alcoholism last March. Together with another Dr Renaud de Beaurepaire (Centre Hospitalier Paul-Guiraud in Villejuif, near Paris), one of the first to have prescribed high doses of baclofen in France, Philippe Jaury studied 181 heavy alcohol consumers, of whom a followup evaluation was possible for 132. After one year of baclofen initiation, 80% of 132 patients had become either abstinent (78), or moderate low- risk drinkers (28). Even after considering as ‘failures’ the patients with whom contact was lost, (meaning a complete evaluation was impossible), the rate of success still stands at 58%. ‘This allows us to think that it’s more efficient than what we have now,’ Philippe Jaury concludes.

The rate of success after one year, with the two most used drug today, naltrexone and acamprosate, stands between 20 and 25%. That preliminary study opened the way for a comparative clinical trial taking place between May 2012 and the end of 2013. This double-blind randomised controlled study is directed by Philippe Jaury, involves 60 other doctors and includes 320 highrisk drinkers who will be followed for the year, divided into two groups, one using baclofen the other a placebo. That clinical survey (cost: €1.2 million euros) will be financed mostly from Social Security funds (€750,000 euros) and the rest from a private sponsor, according to Dr Jaury.

Baclofen doses will be increased gradually up to 300 milligrams daily, with the aim of suppressing alcohol craving. ‘In the preliminary study, we had gone up to 300, 350, 400 mg,’ Dr Jaury explains. The average efficacy dose on a oneyear basis was between 130 and 140 mg. In his book, Olivier Ameisen reports taking 70 to 160 mg daily, after reaching 270 mg. The most prevalent side effects from high- dose baclofen were tiredness or sleepiness, insomnia, dizziness or digestive problems. ‘It’s a fact that the more we are going to prescribe, the more we should be faced with unwanted effects that could be unusual,’ Dr Jaury admits, although adding, ‘We have a certain hindsight with multiple sclerosis, for which baclofen can be prescribed at high doses.’ Referring to intense information exchange on numerous websites, Dr Jaury stresses: ‘We’re under strong pressure from alcoholics.’
 

10.07.2012

Related articles

Photo

Article •

Oral vaccination against pancreatic tumours

The world’s first gene cancer therapy study of an innovative oral vaccine is underway at the Surgical Clinic of Heidelberg University Hospital.

Photo

Article •

Eradiction of H. pylori protects against stomach cancer

Almost all stomach cancers not related to the heart develop from the stomach ulcer causing bug H. pylori. A Japanese study shows that treatment to eradicate the mikrobe reduces the risk of developing…

Article •

Tuberculosis blood test gains EU approval

TB causes three million deaths annually, ranking it higher than any other infectious disease. And TB has resurged in Europe. In August, the British Thoracic Society, British Lung Foundation and TB…

Related products

Subscribe to Newsletter